Managing heart health is a major challenge for people living with diabetes. While statins are the standard first step, some patients still have high levels of LDL-C, which is the type of cholesterol that can lead to heart problems. For these individuals, finding an effective next step is vital.
A review of clinical trials shows that PCSK9 inhibitors can significantly improve how the body clears this bad cholesterol from the blood. These drugs have shown consistent and promising reductions in major adverse cardiovascular events for patients who struggle to reach their goals with traditional medicine.
While these treatments show promise, they are not a simple fix for everyone. They currently come with high costs and require an injection rather than a pill. Because of these factors, they are primarily seen as a strong option for high-risk patients who cannot tolerate standard therapies or fail to reach their targets.
Common questions
How do PCSK9 inhibitors help people with diabetes?
These drugs work by significantly increasing the clearance of LDL-C, which is a type of bad cholesterol. For people with diabetes who cannot reach their heart health goals using standard medications like statins, these inhibitors offer a promising way to reduce major cardiovascular risks.
Are there any downsides to using PCSK9 inhibitors?
While they are effective at lowering bad cholesterol, these treatments have some practical hurdles. They currently involve high costs and require parenteral administration, which means the medicine must be given as an injection rather than taken as a pill.
Who is the best candidate for this type of treatment?
This therapy is especially promising for high-risk patients with diabetes. It is often considered for those who cannot reach their cholesterol goals with standard treatments or for those who cannot tolerate common medications due to side effects.
